Neurogene (NGNE) Debt Ratio (2013)
Neurogene posted quarterly Debt Ratio of 0.15 for Q4 2013.
Neurogene (NGNE) has 1 years of Debt Ratio data on file, last reported at 0.15 in Q4 2013.
- For the quarter ending Q4 2013, Debt Ratio changed N/A year-over-year to 0.15; the trailing twelve-month figure through Dec 2013 stood at 0.15 (changed N/A YoY), and the FY2013 full-year result was 0.15, changed N/A from the prior year.
- Debt Ratio for Q4 2013 stood at 0.15.
- Across five years, Debt Ratio topped out at 0.15 in Q4 2013 and bottomed at 0.15 in Q4 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.18 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 1.41 |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.05 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 0.15 |